ClinicalTrials.gg
CompletedNCT03181932Updated Dec 16, 2022Results posted

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

A Phase 3 interventional study of Vancomycin inhalation powder and Placebo inhalation powder in MRSA and Cystic Fibrosis, sponsored by Savara Inc.. Completed at 71 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2022-12-16.

Sponsored by Savara Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 717 studies in Cystic Fibrosis with a site in United States — 86 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
67th of 517
188 · median 36
Started
2017
with 33 others
Phase 3
100 of 717
2 open now
Registered
431st of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 67th largest by enrollment of the 517 interventional ones that give a count, is one of 34 that started in 2017, is one of 100 in phase 3, and was the 431st registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

86 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

81 more — sign in →

All 86 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized phase III study to evaluate the clinical effectiveness of AeroVanc in persistent methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis (CF).

Read the detailed description

This is a phase III, randomized, multicenter, double-blind, placebo-controlled, parallel-group study to examine the safety and efficacy of AeroVanc in the treatment of persistent MRSA lung infection in patients diagnosed with CF. After the Screening period to confirm study eligibility, participants are randomly assigned in a blinded fashion to receive either AeroVanc 30 mg twice daily (BID), or placebo BID (1:1 active to placebo) by inhalation for 24 weeks or 3 dosing cycles (Period 1). Upon completion of Period 1, participants receive open-label AeroVanc 30 mg BID for an additional 24 weeks or 3 dosing cycles (Period 2), to evaluate long-term safety of AeroVanc. A dosing cycle is defined as 28 days of treatment followed by 28 days of observation.

Participants on a 28-day cyclical on/off anti-Pseudomonal antibiotic regimen enter the Screening period at a time such that the Baseline visit coincide with the end of their anti-Pseudomonas antibiotic cycle. Study drug is thereby administered during the off-cycle, and participants can then resume anti-Pseudomonal therapy during the 28-day observation period. Participants continuing alternating anti-Pseudomonal therapy can continue their treatment during the study drug administration, and observation period.

The primary and secondary analyses are conducted in participants ≤21 years old. Subjects >21 years old are analyzed separately as supportive analyses.

03

Conditions studied

  • MRSA
  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants ≥6 years of age at time of form or assent form signing.
  2. Confirmed diagnosis of CF, determined by having clinical features consistent with the CF phenotype, plus one of the following:

    1. Positive sweat chloride test (value ≥60 milliequivalent/L),
    2. Genotype with 2 mutations consistent with CF (i.e., a mutation in each of the cystic fibrosis transmembrane conductance regulator genes).
  3. Positive sputum culture or a throat swab culture for MRSA at Screening.
  4. In addition to the Screening sample, have at least 2 prior sputum or throat swab cultures positive for MRSA, of which at least 1 sample is >6 months prior to Screening. At least 50% of all MRSA cultures (sputum or throat swab culture) collected from the time of the first positive culture (in the previous 1 year) must have tested positive for MRSA. (Note: Screening sample may count towards 50% positive count)
  5. ≥30% and ≤90% of predicted that is normal for age, gender, race, and height, using the Global Lung Function Initiative equation.
  6. At least 1 episode of acute pulmonary infection treated with non-maintenance antibiotics within 12 months prior to the Baseline visit (initiation of treatment with intermittent inhaled anti-Pseudomonal therapy will not qualify as treatment with non-maintenance antibiotics).
  7. If female of , an acceptable method of must be used during the study and must be combined with a negative pregnancy test obtained during Screening; sexually active male subjects of who are non-sterile (i.e., male who has not been sterilized by vasectomy for at least 6 months, and were not diagnosed with infertility through demonstration of azoospermia in a semen sample and/or absence of vas deferens through ultrasound) must be willing to use a barrier method of contraception, or their female partner must use an acceptable method of contraception, during the study.

    For purposes of this study, the Sponsor defines "acceptable methods of contraception" as:

    1. Oral birth control pills administered for at least 1 monthly cycle prior to administration of the study drug.
    2. A synthetic progestin implanted rod (eg, Implanon®) for at least 1 monthly cycle prior to the study drug administration but not beyond the 4th successive year following insertion.
    3. Intrauterine devices, inserted by a qualified clinician for at least 1 monthly cycle prior to study drug administration.
    4. Medroxyprogesterone acetate (eg, Depo-Provera®) administered for a minimum of 1 monthly cycle prior to administration of the study drug and continuing through 1 month following study completion.
    5. Hysterectomy or surgical sterilization.
    6. Abstinence.
    7. Double barrier method (diaphragm with spermicidal gel or condoms with contraceptive foam).

    Note: For subjects prescribed Orkambi: Orkambi may substantially decrease hormonal contraceptive exposure, reducing the effectiveness and increasing the incidence of menstruation-associated adverse reactions. Hormonal contraceptives, including oral, injectable, transdermal, and implantable, should not be relied upon as an effective method of contraception when co-administered with Orkambi.

  8. Able and willing to comply with the protocol, including availability for all scheduled study visits and able to perform all techniques necessary to use the AeroVanc inhaler and measure lung function.
  9. Agree not to smoke during any part of the clinical trial (Screening visit through end of study).
  10. Participants with a Pseudomonas aeruginosa co-infection must either be stable on a regular suppression regimen of inhaled antibiotics or must be, in the opinion of the Investigator, stable despite the lack of such treatment.

Exclusion criteria

Exclusion criteria

  1. Use of anti-MRSA treatments prescribed as maintenance therapy (intravenous [IV] or inhaled treatment within 28 days; oral treatment within 14 days) prior to the Baseline visit.
  2. Use of non-maintenance antibiotic for pulmonary infection or extrapulmonary MRSA infection (IV or inhaled antibiotic within 28 days; oral antibiotic within 14 days) prior to the Baseline visit.
  3. History of previous allergies or sensitivity to vancomycin, or other component(s) of the study drug or placebo except for a history of red-man syndrome.
  4. Inability to tolerate inhaled products.
  5. First time sputum culture or throat swab culture yielding Burkholderia cepacia, or nontuberculous Mycobacteria in the previous 6 months to Screening.
  6. History of lung or other solid organ transplantation or currently on the list to receive lung or other solid organ transplantation.
  7. Resistance to vancomycin at Screening (vancomycin resistant Staphylococcus aureus, or vancomycin intermediate resistant Staphylococcus aureus, with minimum inhibitory concentration ≥8 μg/mL).
  8. Oral in doses exceeding 10 mg prednisone per day or 20 mg prednisone every other day, or equipotent doses of other corticosteroids.
  9. Changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid medications within 14 days, or changes in cystic fibrosis transmembrane conductance modulators within 28 days, prior to the Baseline visit.
  10. Abnormal laboratory findings or other findings or medical history at Screening that, in the Investigator's opinion, would compromise the safety of the subject or the quality of the study data.
  11. Inability to tolerate inhalation of a short acting beta2 agonist
  12. Oxygen saturation \<90% at Screening.
  13. Changes in physiotherapy technique or physiotherapy scheduled within 1 week of the Baseline visit.
  14. Administration of any drug or device within 4 weeks prior to the Screening visit and during the study
  15. Female with positive pregnancy test result during Screening, pregnant (or intends to become pregnant), lactating or intends to breastfeed during the study.
  16. Renal insufficiency, defined as \<50 mL/min using the Cockcroft-Gault equation for adults or Schwartz equation for children at the Screening visit.
  17. Abnormal liver function, defined as ≥4x of serum or serum alanine aminotransferase, or known cirrhosis at Screening.
  18. Diagnosed with hearing loss.
  19. History of positive result for , virus or virus.
  20. Planned hospitalizations for prophylaxis antibiotic treatment within 28 days prior to Baseline visit or during the double-blind period (Period 1).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Double-blind vancomycin inhalation powder

    Vancomycin inhalation powder 30 mg is administered twice daily (BID) during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.

    Drug: Vancomycin inhalation powder

  • Placebo comparator
    Double-blind placebo inhalation powder

    Matching placebo is administered BID during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.

    Drug: Placebo inhalation powder

  • Experimental
    Open-label vancomycin inhalation powder

    In the 24-week Period 2, all participants receive AeroVanc 30 mg BID by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.

    Drug: Vancomycin inhalation powder

Interventions

  • DrugVancomycin inhalation powder

    100 participants are to be treated with double-blind vancomycin inhalation powder (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.

    Also known as: AeroVanc

  • DrugPlacebo inhalation powder

    100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.

  • DrugVancomycin inhalation powder

    In the 24-week Period 2, all participants are to be treated with open-label vancomycin inhalation powder.

    Also known as: AeroVanc

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted

    The mean absolute change from baseline in FEV1 percent predicted was analyzed sequentially at Week 4 (end of Cycle 1), Week 12 (end of Cycle 2) and at Week 20 (end of Cycle 3).

    Time frame: Baseline and Week 4, 12 and 20

Secondary outcomes

  1. Frequency of Pulmonary Exacerbations

    The number of pulmonary exacerbations during Period 1 adjusted for the length of follow-up.

    Time frame: Week 20

  2. Time to First Pulmonary Exacerbation

    Time to first pulmonary exacerbation requiring use of another antibiotic medication (oral, IV, and/or inhaled). The Outcome Measure Data presented are the median percentiles and 95% confidence intervals from Kaplan-Meier estimates.

    Time frame: Week 20

  3. Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Scores

    The CFQ-R was administered every two weeks using a hand-held e-Diary. CFQ-R scores range between 0 and 100, where higher scores indicate a better outcome. The CFQ-R measures functioning in a variety of domains, including Physical Functioning, Vitality, Health Perceptions, Respiratory Symptoms, Treatment Burden, Role Functioning, Emotional Functioning and Social Functioning. The Outcome Measure Data presented are the Respiratory Symptoms Scores.

    Time frame: Baseline and Week 4, 12, and 20

  4. Change From Baseline in Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Symptom Score (CFRSD-CRISS) Scores

    The CFRSD-CRISS was administered every two weeks using a hand-held e-Diary. Scores range between 0 and 100, where higher scores indicate a worse outcome.

    Time frame: Baseline and Week 4, 12 and 20

  5. Relative Change in FEV1 Percent Predicted

    The mean relative change from Baseline in FEV1 percent predicted

    Time frame: Baseline and Week 4, 12 and 20

  6. Number of Successful Response Cycles

    The number of successful response cycles a participant achieves over Period 1. A response in a cycle is defined by at least a 5 % relative improvement in FEV1 percent predicted at the end of each the respective cycle.

    Time frame: Week 20

  7. Area Under the FEV1-time Profile

    The mean treatment difference in FEV1 across all post-baseline visits

    Time frame: Week 20

07

Results

Posted Nov 5, 2021
Limitations and caveats
A total of 200 participants were to be randomized. Consequent to the outbreak of COVID-19, the recruitment was stopped prematurely when 188 participants had been randomized. The CFQ-R and CFRSD-CRISS were administered every two weeks using a hand-held e-Diary. The e-Diary had not been activated at the baseline visit for 39 participants. For these participants, missing baseline measurements were imputed with the population median baseline value for inferential analyses.

Participant flow

76 sites in Canada (2 clinics) and US (74 clinics) enrolled participants in the trial. First participant was enrolled on 20 September 2017 and last subject completed the study on 15 January 2021.

Period 1 (Double-blind Period)
Participant flow — Period 1 (Double-blind Period)
MilestoneDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation Powder
Started9098
Completed7985
Not completed1113
Withdrew: Adverse event51
Withdrew: Lost to follow-up01
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject59
Period 2 (Open-label Period)
Participant flow — Period 2 (Open-label Period)
MilestoneDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation Powder
Started7583
Completed6770
Not completed813
Withdrew: Adverse event16
Withdrew: Lost to follow-up01
Withdrew: Protocol violation31
Withdrew: Withdrawal by subject25
Withdrew: Reason missing20

Outcome measures

PrimaryAbsolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted

The mean absolute change from baseline in FEV1 percent predicted was analyzed sequentially at Week 4 (end of Cycle 1), Week 12 (end of Cycle 2) and at Week 20 (end of Cycle 3).

Time frame:
Baseline and Week 4, 12 and 20
Reported as:
Mean · Percent predicted
Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted
Percent predictedDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation Powder
Week 42.39 ± 8.0781.18 ± 8.581
Week 121.52 ± 8.4140.13 ± 8.056
Week 201.61 ± 9.967-1.94 ± 8.924
Statistical analysis
  • Double-blind Vancomycin Inhalation Powder vs Double-blind Placebo Inhalation Powder · Mixed Models Analysis · p = 0.325 · Least square mean difference: 1.4 · 95% CI -1.4 to 4.1
SecondaryFrequency of Pulmonary Exacerbations

The number of pulmonary exacerbations during Period 1 adjusted for the length of follow-up.

Time frame:
Week 20
Reported as:
Mean · exacerbations
Frequency of Pulmonary Exacerbations
exacerbationsDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation Powder
Frequency of Pulmonary Exacerbations0.9 ± 1.030.9 ± 1.02
SecondaryTime to First Pulmonary Exacerbation

Time to first pulmonary exacerbation requiring use of another antibiotic medication (oral, IV, and/or inhaled). The Outcome Measure Data presented are the median percentiles and 95% confidence intervals from Kaplan-Meier estimates.

Time frame:
Week 20
Reported as:
Median · days
Time to First Pulmonary Exacerbation
daysDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation Powder
Time to First Pulmonary Exacerbation38 (18 to 49)48 (29 to 59)
SecondaryChange From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Scores

The CFQ-R was administered every two weeks using a hand-held e-Diary. CFQ-R scores range between 0 and 100, where higher scores indicate a better outcome. The CFQ-R measures functioning in a variety of domains, including Physical Functioning, Vitality, Health Perceptions, Respiratory Symptoms, Treatment Burden, Role Functioning, Emotional Functioning and Social Functioning. The Outcome Measure Data presented are the Respiratory Symptoms Scores.

Time frame:
Baseline and Week 4, 12, and 20
Reported as:
Least squares mean · score on a scale
Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Scores
score on a scaleDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation Powder
Week 48.4 (4.2 to 12.7)3.0 (-1.0 to 7.0)
Week 126.0 (1.4 to 10.6)4.3 (-0.2 to 8.9)
Week 204.6 (-0.8 to 10.1)6.3 (1.2 to 11.4)
SecondaryChange From Baseline in Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Symptom Score (CFRSD-CRISS) Scores

The CFRSD-CRISS was administered every two weeks using a hand-held e-Diary. Scores range between 0 and 100, where higher scores indicate a worse outcome.

Time frame:
Baseline and Week 4, 12 and 20
Reported as:
Least squares mean · score on a scale
Change From Baseline in Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Symptom Score (CFRSD-CRISS) Scores
score on a scaleDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation Powder
Week 4-3.2 (-7.3 to 0.9)-5.1 (-9.1 to -1.1)
Week 12-4.7 (-10.1 to 0.6)-8.0 (-13.3 to -2.8)
Week 20-7.3 (-12.5 to -2.0)-5.3 (-10.3 to -0.4)
SecondaryRelative Change in FEV1 Percent Predicted

The mean relative change from Baseline in FEV1 percent predicted

Time frame:
Baseline and Week 4, 12 and 20
Reported as:
Least squares mean · percent predicted
Relative Change in FEV1 Percent Predicted
percent predictedDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation Powder
Week 42.9 (-1.0 to 6.8)1.5 (-2.1 to 5.1)
Week 121.2 (-2.8 to 5.2)-0.3 (-4.1 to 3.5)
Week 201.7 (-2.7 to 6.1)-2.2 (-6.4 to 2.0)
SecondaryNumber of Successful Response Cycles

The number of successful response cycles a participant achieves over Period 1. A response in a cycle is defined by at least a 5 % relative improvement in FEV1 percent predicted at the end of each the respective cycle.

Time frame:
Week 20
Reported as:
Count of participants · Participants
Number of Successful Response Cycles
ParticipantsDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation Powder
0 successful response cycles2024
1 successful response cycle1827
2 successful response cycles159
3 successful response cycles96
SecondaryArea Under the FEV1-time Profile

The mean treatment difference in FEV1 across all post-baseline visits

Time frame:
Week 20
Reported as:
Least squares mean · percent predicted*hour/liter
Area Under the FEV1-time Profile
percent predicted*hour/literDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation Powder
Area Under the FEV1-time Profile609.7 (520.8 to 698.7)583.1 (499.8 to 666.5)

Adverse events

Collected over Treatment-emergent adverse events (AEs) were assessed on or after the first dose of trial drug to 28 days after last dose. For all safety analyses, a single set of results was produced including all participants (6-21 and >21 years combined). For the double-blind Period 1, AE data are presented for the vancomycin and placebo groups whereas for the open-label Period 2, AE data for only one combined group is presented.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Vancomycin Inhalation Powder0/90 (0%)24/90 (26.7%)85/90 (94.4%)
Double-blind Placebo Inhalation Powder0/98 (0%)35/98 (35.7%)93/98 (94.9%)
Open-label Vancomycin Inhalation Powder0/158 (0%)50/158 (31.6%)139/158 (88%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation PowderOpen-label Vancomycin Inhalation Powder
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations19/9029/9838/158
ConstipationGastrointestinal disorders2/904/982/158
PneumoniaInfections and infestations2/903/983/158
HaemoptysisRespiratory, thoracic and mediastinal disorders1/902/982/158
BronchitisInfections and infestations0/900/983/158
Pneumonia staphylococcalInfections and infestations1/901/980/158
InfluenzaInfections and infestations1/900/980/158
Staphylococcal infectionInfections and infestations1/900/980/158
AsthmaRespiratory, thoracic and mediastinal disorders1/900/980/158
Cystic fibrosis related diabetesCongenital, familial and genetic disorders1/900/980/158
Most frequent other events
Showing 10 of 26
Most frequent other events
EventDouble-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation PowderOpen-label Vancomycin Inhalation Powder
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations51/9059/9878/158
CoughRespiratory, thoracic and mediastinal disorders42/9036/9840/158
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/9012/989/158
HeadacheNervous system disorders9/9012/9812/158
PyrexiaGeneral disorders11/908/988/158
VomitingGastrointestinal disorders9/9011/980/158
Nasal congestionRespiratory, thoracic and mediastinal disorders7/9010/988/158
NauseaGastrointestinal disorders4/9010/988/158
Chest discomfortGeneral disorders9/908/980/158
WheezingRespiratory, thoracic and mediastinal disorders3/908/987/158

Baseline characteristics

The number of baseline participants include both age groups (participants 6-21 years and \>21 years).

Age, Continuous
Age, Continuous(years)Double-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation PowderTotal
Mean20.2 ± 12.5218.2 ± 8.7019.2 ± 10.71
Age, Customized
Age, Customized(Participants)Double-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation PowderTotal
6-21 years6469133
>21 years262955
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation PowderTotal
Female455095
Male454893
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation PowderTotal
Hispanic or Latino4610
Not Hispanic or Latino8692178
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation PowderTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American314
White8594179
More than one race000
Unknown or Not Reported224
Pseudomonas Aeruginosa Infection Present at Screening (Yes/No?)
Pseudomonas Aeruginosa Infection Present at Screening (Yes/No?)(Participants)Double-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation PowderTotal
Yes514596
No395392
Number of Pulmonary Infections in the Previous Year
Number of Pulmonary Infections in the Previous Year(infections)Double-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation PowderTotal
Mean2.6 ± 1.532.6 ± 1.442.6 ± 1.48
Baseline Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted
Baseline Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted(percent predicted)Double-blind Vancomycin Inhalation PowderDouble-blind Placebo Inhalation PowderTotal
Mean65.25 ± 16.19366.32 ± 16.93965.81 ± 16.550
08

Study locations

71 sites
  • Pulmonary Associates of Mobile
    Mobile, Alabama 36608, United States
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Miller Childrens Hospital MemorialCare Health System Pediatric Pulmonology
    Long Beach, California 90806, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • University of Southern California Keck Medical Center of USC
    Los Angeles, California 90033, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • National Jewish Health Adult Cystic Fibrosis Center
    Denver, Colorado 80206, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • University of Florida Pediatrics
    Gainesville, Florida 32610, United States
  • Memorial Healthcare System
    Hollywood, Florida 33021, United States
  • Nemours Childrens Specialty Care
    Jacksonville, Florida 32207, United States
  • University of Miami Bachelor Children's Hospital
    Miami, Florida 33136, United States
  • Central Florida Pulmonary Group
    Orlando, Florida 32803, United States
  • Arnold Palmer Hospital Pulmonary and Sleep Medical Institute Orlando Health, Inc
    Orlando, Florida 32806, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Nemours Children's Specialty Care
    Pensacola, Florida 32514, United States
  • Johns Hopkins All Children's Hospital
    Saint Petersburg, Florida 33701, United States
  • Children's Health Care of Atlanta at Scottish Rite
    Atlanta, Georgia 30342, United States
  • Augusta Univ Cystic Fibrosis Center
    Augusta, Georgia 30912, United States
  • Chicago CF Care Specialists
    Glenview, Illinois 60025, United States
  • NorthSurburban Pulmonary Specialists
    Morton Grove, Illinois 60053, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • University of Iowa Department of Pediatrics
    Iowa City, Iowa 52242, United States
  • University of Kansas
    Kansas City, Kansas 66160, United States
  • Via Christi Health Systems CF Clinic
    Wichita, Kansas 67214, United States
  • University of Louisville Kosair Charities Pediatric Clinical Research Unit
    Louisville, Kentucky 40202, United States
  • Maine Medical Partners Pediatric Specialty Care
    Portland, Maine 04102, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Wayne State University (HUH)
    Detroit, Michigan 48201, United States
  • Children's Mercy
    Kansas City, Missouri 64108, United States
  • Cardinal Glennon Children's Hospital /Saint Louis University
    Saint Louis, Missouri 63104, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Rutgers-Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • University of New Mexico Pediatric/Pulmonary
    Albuquerque, New Mexico 87131, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Northwell Health, Div of Pulmonary, Critical Care & Sleep Medicine
    New Hyde Park, New York 11042, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Levine Children's Hospital - Atrium Health
    Charlotte, North Carolina 28203, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Wake Forest School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • University Hospital Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • The Research Institute at Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Dayton Children's Hospital
    Dayton, Ohio 45404, United States
  • Toledo Children's Hospital CF Center
    Toledo, Ohio 43606, United States
  • University of Oklahoma Health Science Center - Pediatric Pulmonary & CF Center
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Penn State Children's Hospital
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMCU
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Sanford Childrens Specialty Clinic
    Sioux Falls, South Dakota 57105, United States
  • UTHSC Lebonheur Children's Hospital
    Memphis, Tennessee 38103, United States
  • Austin Children's Chest Associates
    Austin, Texas 78723, United States
  • Children's Medical Center Cystic Fibrosis Clinic
    Dallas, Texas 75235, United States
  • Cook Children Medical Center
    Fort Worth, Texas 76104, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Tyler
    Tyler, Texas 75708, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84132, United States
  • University Vermont Medical Center Vermont Lung Center
    Colchester, Vermont 05446, United States
  • University of Virginia Health System, Cystic Fibrosis Center
    Charlottesville, Virginia 22908, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Providence Medical Research Center
    Spokane, Washington 99204, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • British Columbia Children's Hospital
    Vancouver, British Columbia V6H 3V4, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Jul 2020, 34 months.

Results were first posted in Nov 2021, 1 year 3 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 34 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2017
First posted
Jun 9, 2017
StartActual
Sep 20, 2017
Primary completionActual
Jul 28, 2020
CompletionActual
Jan 15, 2021
Results first posted
Nov 5, 2021
Last update
Dec 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03181932
Lead sponsor
Savara Inc.
Responsible party
Sponsor
First posted
Jun 9, 2017
Start date
Sep 20, 2017
Primary completion
Jul 28, 2020
Completion
Jan 15, 2021
Results posted
Nov 5, 2021
Last update
Dec 16, 2022

Study contacts

Patrick Flume, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion